
European Journal of Medicinal Chemistry p. 789 - 797 (1998)
Update date:2022-07-29
Topics:
Dal Piaz, Vittorio
Giovannoni, Maria Paola
Castellana, Carla
Palacios, Jose Maria
Beleta, Jorge
Domenech, Teresa
Segarra, Victor
A novel group of heterocyclic-fused 3(2H)-pyridazinones were synthesized and evaluated as PDE III and PDE IV inhibitors and their affinity for 3H Rolipram high affinity binding site was determined. The obtained data demonstrated that some of the new compounds are endowed with potent and selective PDE IV inhibitory activity and greatly attenuated affinity for the Rolipram high affinity binding site that seems to be responsible for unwanted effects. Theoretical calculations, performed on representative compounds, demonstrated the presence of three hydrogen-bonding acceptor regions, of which one looks quite different with respect to literature compounds. This finding could explain the different pharmacological profile of the title compounds with respect to the analogs reported in the literature.
View MoreShanghai Balmxy Pharmaceutical Co., Ltd
Contact:0086-21-24206007
Address:Room 402, 15#, No. 909 wangyue Road, shanghai, P. R. China
Hunan Dinuo Pharmaceutical Co.,Ltd.
Contact:86-731-88280100*8561
Address:Bio-pharmaceutical industrial park, Liuyang, Hunan, China
Zhejiang Quzhou Zhengbang Organosilicon Co.,ltd.
Contact:86-570-3375195
Address:No.17 Lingqing Road technology industry,Quzhou City,Zhejiang Province,China
Kaymossy BioChem Tech Co., Ltd
website:http://www.kaimosi.com
Contact:0571-87191913/0571-87199097
Address:Room 215, Building 3rd, No.288 Ningxia Road, Qingdao city, China
Hefei Highzone Fine Chemical S&T CO.,LTD
Contact:86-0551-63663560
Address:room 1801 NO. 24 Shuguang RD.
Doi:10.1021/ja00149a011
(1995)Doi:10.1016/j.tetlet.2014.03.004
(2014)Doi:10.1055/s-1994-25545
(1994)Doi:10.1016/j.tet.2014.03.037
(2014)Doi:10.1039/c4cc00857j
(2014)Doi:10.1016/j.molcata.2014.01.005
(2014)